Agouron Pharmaceuticals (AGPH) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Agouron Pharmaceuticals (AGPH)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: JimieA who wrote (5572)	10/21/1998 1:05:00 PM
From: Joe E.	of 6136

Jim: The idea that one can stop taking anti-viral drugs after a period has been tested before without success, at least for those with established infections. This current test is for someone with a short period of infection. Maybe it will work. I seems similar to the aproach used with medical personnel who get an exposure from a needle stick. I think that it is but one test of the dozens underway that might affect Viracept sales some day. By itself probably not important (expecially with an n of one) but a reminder that the value of Agouron is not only Viracept (which eventually must fade) but the research they have underway. Similarly the cancer research. There are even more people working on cancer than on HIV. AG3340 will definitely not be the last word on cancer treatment. We can just hope that it has its day in the sun, lets some people live longer, and makes some money for Agouron to invest in the next thing. It is likely (IMO) that vaccines will ultimately be used to prevent both HIV and many cancers, but they both seem a long way off right now.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next